Skip to main content

Advertisement

SpringerLink
Log in

D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale and objective

The relationship between clinically effective antipsychotic drugs in obsessive–compulsive disorders (OCD) and binding affinities to cloned dopamine and serotonin receptor subtypes was analyzed in an effort to clarify the contribution of individual receptor subtypes to medication response.

Methods

Meta-analysis was used to update previous meta-analyses of effectiveness data of add-on antipsychotic drugs to selective serotonin reuptake inhibitors (SSRIs) in OCD. Twelve previously analyzed randomized controlled trials (RCTs) and one new RCT were included. We performed a metaregression using a mixed-effect model to examine the association between antipsychotic’s effectiveness and receptor affinity.

Results

A total of 5 treatment arms obtained from 13 RCTs (431 patients) were included in our study. The results of our metaregression showed a significant association between D2 and D3 dopamine receptor affinities and effectiveness in OCD (respectively, slope = −0.36, p = 0.01; and slope = −0.50, p = 0.01) whereas other dopamine receptors and serotonin receptors were not significantly associated.

Conclusions

These observations suggest that increasing D2 and D3 dopamine receptor binding affinities enhances antipsychotics’ effectiveness in obsessive–compulsive disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References

  • AFSSAPS (2006) Good use of antidepressants in the treatment of depressive and anxiety disorders in adults. http://ansm.sante.fr/var/ansm_site/storage/original/application/9698d423c76ea69ed0a2678ff7a2b2b3.pdf. Accessed 5 Oct 2013

  • APA APA (2013) Diagnostic and statistical manual of mental disorders: fifth edition DSM5.

  • Atmaca M, Kuloglu M, Tezcan E, Gecici O (2002) Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 17:115–119

    Article  CAS  PubMed  Google Scholar 

  • Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11:622–632

    Article  CAS  PubMed  Google Scholar 

  • Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to meta-analysis. Wiley, Chichester, UK

    Book  Google Scholar 

  • Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S (2004) Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 65:565–568

    Article  CAS  PubMed  Google Scholar 

  • Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ (2005) Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatr 5:5

    Article  Google Scholar 

  • Collins PY, Insel TR, Chockalingam A, Daar A, Maddox YT (2013) Grand challenges in global mental health: integration in research, policy, and practice. PLoS Med 10:e1001434

    Article  PubMed Central  PubMed  Google Scholar 

  • Denys D, de Geus F, van Megen HJ, Westenberg HG (2004a) A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040–1048

    Article  CAS  PubMed  Google Scholar 

  • Denys D, de Vries F, Cath D, Figee M, Vulink N, Veltman DJ, van der Doef TF, Boellaard R, Westenberg H, van Balkom A, Lammertsma AA, van Berckel BN (2013) Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder. Eur Neuropsychopharmacol : The Journal of the European College of Neuropsychopharmacology 23:1423–1431

    Article  CAS  Google Scholar 

  • Denys D, Van Nieuwerburgh F, Deforce D, Westenberg H (2006) Association between the dopamine D2 receptor TaqI A2 allele and low activity COMT allele with obsessive-compulsive disorder in males. Eur Neuropsychopharmacol: The Journal of the European College of Neuropsychopharmacology 16:446–450

    Article  CAS  Google Scholar 

  • Denys D, Zohar J, Westenberg HG (2004b) The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. J Clin Psychiatry 65(Suppl 14):11–17

    CAS  PubMed  Google Scholar 

  • Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC (2011) A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. J Clin Psychopharmacol 31(6):763–8. doi:10.1097/JCP.0b013e3182367aee

    Google Scholar 

  • Dold M, Aigner M, Lanzenberger R, Kasper S (2013) Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol/ Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum 16:557–574

    Article  CAS  Google Scholar 

  • Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L (2005) Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol: The Journal of the European College of Neuropsychopharmacology 15:69–74

    Article  CAS  Google Scholar 

  • Fineberg NA, Gale TM (2005) Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol/ Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum 8:107–129

    Article  CAS  Google Scholar 

  • Hollander E, Kaplan A, Stahl SM (2003) A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry: The Official Journal of the World Federation of Societies of Biological Psychiatry 4:30–34

    Article  Google Scholar 

  • Karayiorgou M, Sobin C, Blundell ML, Galke BL, Malinova L, Goldberg P, Ott J, Gogos JA (1999) Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder. Biol Psychiatry 45:1178–1189

    Article  CAS  PubMed  Google Scholar 

  • Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F (2008) Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol 28:550–554

    Article  CAS  PubMed  Google Scholar 

  • McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000) A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57:794–801

    Article  CAS  PubMed  Google Scholar 

  • McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994) Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302–308

    Article  CAS  PubMed  Google Scholar 

  • Metin O, Yazici K, Tot S, Yazici AE (2003) Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol 18:463–467

    Article  CAS  PubMed  Google Scholar 

  • Muscatello MR, Bruno A, Pandolfo G, Mico U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA (2011) Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol 31:174–179

    Article  CAS  PubMed  Google Scholar 

  • Perani D, Garibotto V, Gorini A, Moresco RM, Henin M, Panzacchi A, Matarrese M, Carpinelli A, Bellodi L, Fazio F (2008) In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder. NeuroImage 42:306–314

    Article  PubMed  Google Scholar 

  • Pirot S (1998) TOC et sérotonine: données contradictoires actuelles et perspectives thérapeutiques. Neuropsychiatrie: Tendances et Débats 3:39–43

    Google Scholar 

  • Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK (2007) Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology: Official publication of the American College of Neuropsychopharmacology 32:1715–1726

    Article  CAS  Google Scholar 

  • Roth BL, Lopez E, Beischel S, Westkaemper RB, Evans JM (2004) Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther 102:99–110

    Article  CAS  PubMed  Google Scholar 

  • Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A (2012) Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). Depress Anxiety 29:850–854

    Article  CAS  PubMed  Google Scholar 

  • Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, Goodman WK (2004) A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 55:553–555

    Article  CAS  PubMed  Google Scholar 

  • Somers JM, Goldner EM, Waraich P, Hsu L (2006) Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 51:100–113

    PubMed  Google Scholar 

  • Ugedo L, Grenhoff J, Svensson TH (1989) Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98:45–50

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Katie Steel for her careful editorial assistance.

Funding source

None.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. INSERM U1061, Université Montpellier 1, Service Universitaire de Psychiatrie Urgence et Post-urgence, CHU Montpellier, Montpellier, 34000, France

    Deborah Ducasse, Alexandra Macgregor, Philippe Courtet & Guillaume Fond

  2. EA 3279-Self-perceived Health Assessment Research Unit, School of Medicine, La Timone University, 13005, Marseille, France

    Laurent Boyer, Pierre Michel & Anderson Loundou

  3. AP-HP, GHU Mondor, DHU Pepsy, Université Paris-Est, Fondation FondaMental, Fondation de Coopération Scientifique en santé mentale, INSERM U955 Eq 15, Creteil, 94000, France

    Marion Leboyer

  4. Pôle Psychiatrie Universitaire, CHU Sainte-Marguerite, 13274, Marseille Cedex 09, France

    Jean-Arthur Micoulaud-Franchi

  5. CHU Carémeau, Nîmes, 30000, France

    Mocrane Abbar

Authors
  1. Deborah Ducasse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurent Boyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pierre Michel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anderson Loundou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alexandra Macgregor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-Arthur Micoulaud-Franchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Philippe Courtet
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mocrane Abbar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Marion Leboyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Guillaume Fond
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guillaume Fond.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ducasse, D., Boyer, L., Michel, P. et al. D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Psychopharmacology 231, 3765–3770 (2014). https://doi.org/10.1007/s00213-014-3516-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-014-3516-3

Keywords

Search

Navigation